Company & Sponsor Intelligence

Sangamo Therapeutics

Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.

Request enterprise analysis →

Indexed trials3

Recruiting0

Completed3

Countries1

Therapeutic footprint

alzheimersparkinsons

Indexed studies

NCT00400634Double-Blind, Multicenter, Sham Surgery Controlled Study of CERE-120 in Subjects With Idiopathic Parkinson's Disease
parkinsons · United StatesPHASE2

NCT00985517Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease
parkinsons · United StatesPHASE1, PHASE2

NCT00087789CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease
alzheimers · United StatesPHASE1

Intelligence layer updated: 2026-10-14 06:11:28.884102+00:00

Enterprise intelligence

Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.

Request comparative intelligence →